CD8A and diffuse large B-cell lymphoma: Recent studies in DLBCL patients treated with Axi-cel showed an association between lack of response and infusion of CART19 products with high proportion of CD8+ CAR19 T cells expressing TIM-3 and LAG-3 (81).